A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia:The GRAALL-SA1 study

Haematologica

Volumn 96, Issue 2, 2011, Pages 245-252

  Hunault Berger, Mathilde ^a   Leguay, Thibaut ^a   Thomas, Xavier ^b   Legrand, Ollivier ^c   Huguet, Françoise ^c   Bonmati, Caroline ^d   Escoffre Barbe, Martine ^c   Legros, Laurence ^d   Turlure, Pascal ^c   Chevallier, Patrice ^c   Larosa, Fabrice ^c   Garban, Frederic ^c   Reman, Oumedaly ^c   Rousselot, Philippe ^c   Dhédin, Nathalie ^e   Delannoy, André ^d   Lafage Pochitaloff, Marina ^f   Béné, Marie Christine ^g   Ifrah, Norbert ^h  

^a Hematology Departments of Angers   (France)

^b Hematology Department   (France)

^c HÔTEL DIEU   (France)

^d Hotel Dieu AP HP Nice ^*  (Belgium)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^g Immunology Department of Nancy   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Acute lymphoblastic leukemia; Continuous infusion; Elderly; Pegylated liposomal doxorubicin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FIBRINOGEN; HYDROCORTISONE; LACTATE DEHYDROGENASE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTEREMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CANDIDEMIA; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CONTINUOUS INFUSION; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG TOLERABILITY; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; INFECTION; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LUNG ASPERGILLOSIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SIDE EFFECT; SKULL IRRADIATION; SYSTEMIC MYCOSIS; THROMBOCYTOPENIA; TRIPLOIDY; URINARY TRACT INFECTION; ZYGOMYCOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 79551637240     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.027862     Document Type: Article

References (44)

1. Taylor PR, Reid MM, Bown N, Hamilton PJ, Proctor SJ. Acute lymphoblastic leukemia in patients aged 60 years and over: a population- based study of incidence and outcome. Blood. 1992;80(7):1813-7.
2. Legrand O, Marie JP, Marjanovic Z, Cadiou M, Blanc C, Ramond S, et al. Prognostic factors in elderly acute lymphoblastic leukaemia. Br J Haematol. 1997;97(3):596-602.
3. Annino L, Goekbuget N, Delannoy A. Acute lymphoblastic leukemia in the elderly. Hematol J. 2002;3(5):219-23.
4. Thomas X, Olteanu N, Charrin C, Lheritier V, Magaud JP, Fiere D. Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol. 2001;67(2):73-83.
5. Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla S, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood. 1984;64(1):267- 74.
6. Bassan R, Chiodini B, Zucchetti M, Lerede T, Cornelli PE, Cortelazzo S, et al. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results. Haematologica. 1998;83(1):27-33.
7. Kantarjian HM, O'Brien S, Smith T, Estey EH, Beran M, Preti A, et al. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin- dexamethasone (VAD) regimen. Br J Haematol. 1994;88(1):94-100.
8. Carlson R, Sikic B. Continuous infusion or bolus injection in cancer chemotherapy. Ann Int Medicine. 1983;99(6):823-33.
9. Speth P, Linssen P, De Pauw B, De Witte T. Cellular pharmacokinetics of daunomycin administered as continuous intravenous infusion in the treatment of acute non-lymphocytic leukaemia. Br J Haematol. 1986; 63(3):603-5.
10. Garnick M, Weiss G, Steele G, Isreael M, Schade D, Sack M, et al. Clinical evaluation of long-term, continuous infusion doxorubicin. Cancer Treat Rep. 1983;67(2): 133-42.
11. Koskela K, Pelliniemi TT, Remes K. VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion? Leuk Lymphoma. 1993;10(4-5):347-51.
12. Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan- Kettering-New York-II protocol. Cancer. 1993;72(10):3120-30.
13. DeGregorio MW, Carrera CJ, Klock JC, Pegelow CH, Wilbur JR. Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia. Cancer Treat Rep. 1982; 66(12):2085-8.
14. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16(7):2445-51.
15. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440-9.
16. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol. 1998;9(7):711-6.
17. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer. 2004;100(10):2052-63.
18. Kantarjian HM, Walters RS, Keating MJ, Smith TL, O'Brien S, Estey EH, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990;8(6):994-1004.
19. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
20. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc. 1972;135:185-206.
21. Cox D. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
22. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1998;16:1141-54.
23. Fine JP, Gray RJ. A proportional hazard model for the subdistribution of a competing risk. JASA. 1999;94:496-509.
24. Robak T. Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches. Drugs Aging. 2004;21(12):779-91.
25. Hunault-Berger, Milpied N, Bernard M, Delain M, Desablens B, et al. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen. A randomized study. Leukemia. 2001;15(6): 898-902.
26. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362(9398):1828-38.
27. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710-7.
28. Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92(5):1556-64.
29. Offidani M, Corvatta L, Centurioni R, Leoni F, Malerba L, Mele A, et al. High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia. Hematol J. 2003;4(1):47-53.
30. Delannoy A, Ferrant A, Bosly A, Chatelain C, Doyen C, Martiat P, et al. Acute lymphoblastic leukemia in the elderly. Eur J Haematol. 1990;45(2):90-3.
31. Delannoy A, Sebban C, Cony-Makhoul P, Cazin B, Cordonnier C, Bouabdallah R, et al. Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphoblastic Leukemia. Leukemia. 1997;11(9):1429-34.
32. Delannoy A, Cazin B, Thomas X, Bouabdallah R, Boiron JM, Huguet F, et al. Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remission. Leuk Lymphoma. 2002;43(1):75-81.
33. Spath-Schwalbe E, Heil G, Heimpel H. Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period. Ann Hematol. 1994;69(6):291-6.
34. Ferrari A, Annino L, Crescenzi S, Romani C, Mandelli F. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. Leukemia. 1995;9(10):1643-7.
35. Bassan R, Di Bona E, Lerede T, Pogliani E, Rossi G, D'Emilio A, et al. Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. Leuk Lymphoma. 1996;22(3- 4):295-301.
36. Pagano L, Mele L, Casorelli I, Fianchi L, Di Febo A, Leone G. Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica. 2000;85(12):1327-9.
37. Mandelli F, Annino L, Ferrari A, group. ftG. ALL in elderly: The GIMEMA trials. Ann Hematol. 1995;70 (suppl 2):41.
38. Nagura E, Minami S, Nagata K, Morishita Y, Takeyama H, Sao H, et al. [Analysis of elderly patients, aged 60 years old or over, with acute lymphoblastic leukemia]. Nippon Ronen Igakkai Zasshi. 1999;36(1): 52-8.
39. Gokbuget N, de Wit M, Gerhardt A, Lipp T, Rieder H, Schwartz S, et al Results of a shortened, dose reduced treatment protocol in elderly patients with acute lymphoblastic leukemia. Blood. 2000;96 (Suppl 1):718a.
40. Hussein K, Dahlberg S, Head D, Waddell C, Dabich L, Weick J, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood. 1989; 73(1):57-63.
41. Visani G, Guiducci B, D'Adamo F, Mele A, Nicolini G, Leopardi G, et al. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2005;46(3):477-9.
42. Tsavaris N, Kosmas C, Vadiaka M, Giannouli S, Siakantaris MP, Vassilakopoulos T, et al. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res. 2002;22(3):1845-8.
43. Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer. 2006;106(4):848-58.
44. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, et al. Comparison of Escherichia coli-asparaginase with Erwiniaasparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer- Children's Leukemia Group phase 3 trial. Blood. 2002;99(8):2734-9.